Ellence Research Fund Names 11 Grant Recipients

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 3
Volume 10
Issue 3

PEAPACK, NJ- Pharmacia Oncology has announced the 11 recipients of its first $1 million Ellence Research Fund, aimed at promoting research to advance the use of anthracyclines in various cancer settings. The recipients were chosen by a scientific advisory board composed of leading oncologists. The company has created a second $1 million Ellence Research Fund and is currently accepting research proposals.

PEAPACK, NJ— Pharmacia Oncology has announced the 11 recipients of its first $1 million Ellence Research Fund, aimed at promoting research to advance the use of anthracyclines in various cancer settings. The recipients were chosen by a scientific advisory board composed of leading oncologists. The company has created a second $1 million Ellence Research Fund and is currently accepting research proposals. (For more information, contact Lynn Stoltzfus at lynn.stoltzfus@am.pnu.com.)

The 2001 winners are: Glenn Bubley, MD, Beth Israel Deaconess Medical Center, Boston; Joan Bull, MD, University of Texas-Houston Medical School; Luke Dreisbach, MD, Arizona Cancer Center, Tucson; Phil Gold, MD, Swedish Medical Center Tumor Institute, Seattle; Daniel Haller, MD, University of Pennsylvania Cancer Center, Philadelphia; and Jon Herrington, PhD, Scott and White Memorial Hospital, Temple, Texas.

Also, Peter Kennedy, MD, Kenmar Research Institute, Los Angeles; Pam Khosla, MD, Rush-Presbyterian-St. Luke’s Medical Center, Chicago; Silvana Martino, DO, John Wayne Cancer Institute, Santa Monica, California; Lajos Pusztai, PhD, M.D. Anderson; and Christopher Ryan, MD, University of Chicago.

Recent Videos
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Related Content